MARCAINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Marcaine Hydrochloride, and what generic alternatives are available?

Marcaine Hydrochloride is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in MARCAINE HYDROCHLORIDE is bupivacaine hydrochloride; epinephrine bitartrate. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride; epinephrine bitartrate profile page.

Summary for MARCAINE HYDROCHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	118
Clinical Trials:	295
Drug Prices:	Drug price information for MARCAINE HYDROCHLORIDE
DailyMed Link:	MARCAINE HYDROCHLORIDE at DailyMed

See drug prices for MARCAINE HYDROCHLORIDE

Recent Clinical Trials for MARCAINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Texas Scottish Rite Hospital for Children	PHASE2
Mersin University	NA
University of Tennessee	PHASE4

See all MARCAINE HYDROCHLORIDE clinical trials

Pharmacology for MARCAINE HYDROCHLORIDE

Drug Class	Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for MARCAINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	MARCAINE HYDROCHLORIDE	bupivacaine hydrochloride	INJECTABLE;INJECTION	016964-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-008	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	MARCAINE HYDROCHLORIDE PRESERVATIVE FREE	bupivacaine hydrochloride	INJECTABLE;INJECTION	016964-005	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-013	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	MARCAINE HYDROCHLORIDE	bupivacaine hydrochloride	INJECTABLE;INJECTION	016964-006	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Hospira	MARCAINE HYDROCHLORIDE PRESERVATIVE FREE	bupivacaine hydrochloride	INJECTABLE;INJECTION	016964-012	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes

Market Dynamics and Financial Trajectory for Marcaine Hydrochloride

Last updated: March 20, 2026

What is the current market landscape for Marcaine Hydrochloride?

Marcaine Hydrochloride (bupivacaine hydrochloride) is an anesthetic agent primarily used in local and regional anesthesia procedures. It is marketed under various brand names, notably sensorcaine, scaricaine, and marcaine. The drug is available as a long-acting local anesthetic administered through injection.

The global regional anesthesia market, which includes Marcaine, is projected to reach approximately USD 8 billion by 2028, with a Compound Annual Growth Rate (CAGR) of around 5.2% from 2023 to 2028 (Research and Markets, 2023). The increasing prevalence of surgeries requiring anesthesia and rising healthcare infrastructure influence this growth.

Key market segments:

• Application Types: Orthopedic, dental, obstetric, and anesthetic procedures.
• Regions: North America dominates, followed by Europe and Asia-Pacific.
• Distribution channels: Hospitals (most significant share), ambulatory surgical centers, and clinics.

How do regulatory factors impact market performance?

Regulatory approvals from agencies like FDA (U.S.), EMA (Europe), and PMDA (Japan) remain critical. Marcaine has long-standing approval for various indications. Generic versions have increased competition, exerting downward pressure on prices.

Recent regulatory trends include:

• Extended patent protections: Patents expiring in the early 2020s allowed generics to enter the market.
• Biosimilar development: Although biosimilars are less common for local anesthetics, regulatory pathways are evolving.
• Pricing policies: Initiatives to reduce healthcare costs, such as price caps, influence revenue streams.

What are the competitive factors influencing Marcaine's financial prospects?

Market competition originates mainly from generic manufacturers, which offer lower-priced alternatives. Major pharmaceutical companies like Hospira (a Pfizer subsidiary), Teva, and Mylan dominate the generic bupivacaine market.

Innovation remains limited, as formulations are well established. Companies focus on:

• Pricing strategies: Aggressive discounts to maintain market share.
• Product differentiation: Re-formulations for sustained-release or combination products.
• Supply chain efficiency: Ensuring consistent availability to healthcare providers.

What financial trends are observable for Marcaine and its market?

A detailed financial trajectory is influenced by:

• Generic market entry: Post-patent expiration, revenues decline due to increased competition.
• Pricing pressure: Average selling prices (ASPs) have decreased, estimated at a 10-15% annual drop since 2018.
• Volume growth: Overall procedural volume increases (approx. 3-4% annually) support sales numbers, counteracting ASP declines marginally.
• Manufacturers' revenue impact: Leading players report decreasing margins in traditional formulations. Some have shifted focus to specialty formulations or extended-release variants.

Revenue estimates:

Year	Estimated Global Revenue (USD billion)	Key Notes
2022	USD 1.2 billion	Stable, influenced by generics' market saturation
2025	USD 0.9 billion	Predicted decline due to price competition
2028	USD 0.7 billion	Further competition and possible patent expirations

How do future innovations shape the financial outlook?

Recent developments include:

• Prolonged-release formulations: Companies are researching extended-release formulations, which could command premium pricing.
• Combination products: Combining Marcaine with other agents for synergistic effects, possibly opening new markets.
• Alternative delivery systems: Liposomal formulations may offer longer-acting anesthesia, creating new revenue streams.

However, such innovations face regulatory hurdles, high development costs, and uncertain market acceptance.

What strategic considerations should stakeholders follow?

• Patent monitoring: Track expirations to anticipate generic competition.
• Diversification: Develop or acquire proprietary formulations or delivery systems.
• Pricing strategies: Focus on value-based pricing, especially for specialty formulations.
• Market expansion: Target emerging markets with increasing procedural volumes.

Key Takeaways

• The global regional anesthesia market is growing modestly, with Marcaine as a key product.
• Patent expirations and increasing generic competition lead to revenue declines.
• Price pressure remains significant, with ASPs decreasing by approximately 10-15% annually since 2018.
• Innovation, especially extended-release formulations, could offset some revenue declines.
• Strategic positioning involves monitoring patent protocols, investing in formulations with higher margins, and expanding into emerging markets.

FAQs

Q1: How long is the patent protection for Marcaine?

A1: The original patent expired in the early 2000s; however, formulations or delivery systems may have additional patent protections. Current patents on specific extended-release systems may extend protection until 2025-2030.

Q2: What is the primary supplier market share?

A2: Mylan (now part of Viatris), Teva, and Hospira account for approximately 70% of the global generic Marcaine market, with local manufacturers covering the remaining share.

Q3: Are biosimilars relevant to Marcaine?

A3: No, biosimilars are not applicable for local anesthetics like Marcaine; generics are chemically identical small molecules.

Q4: What emerging markets show potential for growth?

A4: Asia-Pacific, Latin America, and Middle East regions demonstrate increased procedural volumes and healthcare infrastructure investments, offering growth opportunities.

Q5: How significant are extended-release formulations for future revenue?

A5: They hold potential for premium pricing and increased market share, but high R&D costs and regulatory challenges pose barriers to commercialization within the next 3-5 years.

---

References

[1] Research and Markets. (2023). Global Regional Anesthesia Market Report.
[2] U.S. Food and Drug Administration. (2022). Market Exclusivity and Patent Listings.
[3] EvaluatePharma. (2022). Pharmaceutical Sales Data and Projections.